Vaccines Market
Vaccines Market - Global Industry Assessment & Forecast
Segments Covered
- By Technology (excluding COVID 19 vaccines) Conjugate vaccines, Inactivated & Subunit vaccines, Live Attenuated vaccines, Recombinant vaccines, Toxoid vaccines, Viral vector vaccines
- By Technology (including COVID 19 vaccines) mRNA vaccines, Viral Vector vaccines, Others
- By Type Monovalent vaccines, Multivalent vaccines
- By Disease Indication Influenza, Pneumococcal diseases, Combination vaccines, HPV, Herpes Zoster, Meningococcal diseases, Rotavirus, MMR, Varicella, Hepatitis, DTP, Polio, COVID 19, Others
- By Route of Administration Intramuscular & Subcutaneous administration, Oral administration, Others
- By End-user Pediatric vaccines, Adult vaccines
- By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base Year: | 2022 |
Forecast Years: | 2023 - 2030 |
Historical Years: | 2017 - 2021 |
Revenue 2022: | USD 43.80 Billion |
Revenue 2030: | USD 90.52 Billion |
Revenue CAGR (2023 - 2030): | 9.50% |
Fastest Growing Region (2023 - 2030) | Asia Pacific |
Largest Region (2022): | North America |
Customization Offered
- Cross-segment Market Size and Analysis for Mentioned Segments
- Additional Company Profiles (Upto 5 With No Cost)
- Additional Countries (Apart From Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request Customization Speak To Analyst
Research Methodology: Vaccines Market by Technology (excluding COVID 19 vaccines) by Technology (including COVID 19 vaccines) by Type by Disease Indication by Route of Administration by End-user by Region - Global Market Assessment, 2021 - 2028
Secondary Research
Primary Research:
Data Triangulation and Market Size Estimations
FAQ
Frequently Asked Question
What is the global demand for Vaccines in terms of revenue?
-
The global Vaccines valued at USD 43.80 Billion in 2022 and is expected to reach USD 90.52 Billion in 2030 growing at a CAGR of 9.50%.
Which are the prominent players in the market?
-
The prominent players in the market are GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Pfizer Inc. (US), Sanofi SA (France), CSL Limited (Australia), Emergent BioSolutions Inc. (US), Johnson & Johnson (US), AstraZeneca plc (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic A/S (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec, Ltd. (India), Biological E Limited (India), Bharat Biotech Ltd. (India), Novavax Inc. (US), FSUE NPO Microgen (Russia), Sinovac Biotech, Ltd. (China), Incepta Vaccine Limited (Bangladesh), Valneva SE (France), VBI Vaccines (US), PT Bio Farma (Persero) (Indonesia), Inovio Pharmaceuticals Inc. (US), Chongqing Zhifei Biological Products Co., Ltd. (China), Indian Immunologicals Limited (India)..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 9.50% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Vaccines include
- Growing prevalence of emerging and re-emerging infectious diseases
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Vaccines in 2022.